The role of nutrition, gastrointestinal microbiota and a healthy gastrointestinal tract on the autonomy of eldery

• Conditions: C16.9; K58.1; K59.0; K30; G30; C25.9; C18.9; Stomach, unspecified; Irritable bowel syndrome with predominant diarrhoea [IBS-D]; Constipation

• Registration Number: DRKS00009737
• Lead Sponsor: Otto-von-Guericke Universität MagdeburgMedizinische Fakultät

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06-21
• Study Completion: 2017-12-12
• Results First Posted: 2021-07-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 175

Inclusion Criteria

Healthy subjects:
Age > 40 Years

Patients with gastric cancer:
Histologically confirmed Adenocarcinoma of the stomach

Patients with pancreatic cancer:
Histologically confirmed Adenocarcinoma of the pancreas UICC I-IV

Patients with colorectal cancer:
Histologically confirmed colorectal carcinoma UICC I-IV

Patients with functional dyspepsia or irritable bowel Syndrom (IBS):
funcional dyspepsia or IBS according to the Rom-III-criteria

Patients with demenia:
confirmed diagnosis of dementia or neurodegenerative disease

Partner of Patient with dementia:
person living in households with the patient with the diagnosis of dementia

Exclusion Criteria

Healthy subjects:
neurodegenerative diseases;
functional gastrointestinal diseases;
tumor disease in the last 5 years; Serious metabolic or cardiovascular disease requiring therapy (Diabetes mellitus, thyroid disorders, disorders of lipid metabolismus), a medicamentous well-treated arterial hypertension does not represent an exclusion criterium;
antibiotic therapy within the last 8 weeks

Patients with gastric cancer:
additional other tumor disease;
antibiotic therapy within the last 8 weeks

Patients with pancreatic cancer:
additional other tumor disease;
antibiotic therapy within the last 8 weeks

Patients with colorectal cancer:
additional other tumor disease;
antibiotic therapy within the last 8 weeks

Patients with functional dyspepsia or irritable bowel Syndrom (IBS):
antibiotic therapy within the last 8 weeks;
past extensive abdominal operations, chemotherapy, radiotherapy or immunsuppressive therapy within the last 2 years

Patients with dementia:
antibiotic therapy within the last 8 weeks;

Partner of Patient with dementia:
antibiotic therapy within the last 8 weeks;
tumor disease

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To analyze the differences in the composition of gut microbiome in the gastrointestinal tract with regard to the dominant Genera between elderly and patients with functional gastrointestinal diseases, gastric, pancreatic and colorectal cancer, or neurodegenerative diseases.

Secondary Outcome Measures

Name	Time	Method
to analyse: <br>-How does the gut microbiota change during aging?<br>-How does the mucosa-adherent microbiome differ from fecal microbiome after bowel-cleansing ?<br>-Which enviromental factors influence the differences in gut microbiota composition? (residence location in the community, nutrition)?<br>-How does the gut microbiota influence pro- /antiinflammatory mucosal processes?<br>-Does an influence of the gut microbiota on systemic inflammation in the above mentioned populations exist?<br>-How do the above mentioned populations differ with regard to the nutritional anamnesis and the nutritional assessment, and how do these factors influence the gut microbiota?<br>-Can interventional models be developed as a result of the differences detected between the selected populations aiming at therapeutic interventions to correct disease-related dysbiosis?<br>